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Kathryn B. Garber1,*New York’s Experience with Krabbe Newborn
Screening
Several states are on the cusp of initiating newborn
screening for the lysosomal-storage disorder Krabbe dis-
ease, but New York State is ahead of the pack in that it
has been screening for Krabbe disease since 2006. In
work that will be informative to the freshman states add-
ing Krabbe, Orsini et al. present the first 8 years’ worth of
data on New York’s experience, illustrating the challenges
of screening populations for this condition. Although it
was believed that 90% of individuals with Krabbe disease
have either the early-infantile or the late-infantile form,
data from New York suggest that this is not the case and
that fewer have an infantile form of the disease. The screen
ultimately had a positive predictive value of 1.4% for
confirmed infantile Krabbe disease. Also of note, particular
GALC variants were repeatedly detected in the population
with positive screen results, but their significance is still
unclear; they could represent benign alleles with reduced
activity, or they might contribute to later-onset forms of
Krabbe disease. The authors highlight changes they made
to their screening protocol on the basis of their experience,
and these points could be useful as other states design their
screens.
Orsini et al. (2016). Genet. Med. Published online January
21, 2016. http://dx.doi.org/10.1038/gim.2015.211.Lost in Translation
Basic research on fragile X syndrome gave rise to the
metabotropic glutamate receptor (mGluR) theory of fragile
X, which postulated the cause as overactive mGluR
signaling in the absence of FMRP (fragile X mental retarda-
tion protein). Success in using mGluR antagonists to
modulate the resulting phenotype in Fmr1-knockout
mice gave rise to translational research on the impact of
mGluR inhibitors on deficits associated with fragile X syn-
drome. Berry-Kravis et al. report the results of phase 2B
clinical trials of themGluR inhibitormavoglurant in adults
and adolescents with fragile X syndrome. Unfortunately,
no improvements in the behavioral symptoms—the pri-
mary endpoint—were measured over the 12 week trial,
even when subjects were stratified by age or methylation
status at FMR1, which had been suggested from an earlier1Department of Human Genetics, Emory University School of Medicine, Atlan
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The Ametrial. As further detailed in the accompanying commentary
by Jeste and Geschwind, the authors don’t want this po-
tential treatment to get completely lost in translation
and propose tweaks to possible future trial designs,
including enrollment of younger individuals in longer
trials.
Berry-Kravis et al. (2016). Sci. Transl. Med. 8, 321ra5.Being at the Leading Edge Can Be Harmful
Patterns of genetic diversity illustrate human migratory
patterns—increased diversity in Africa and less as the dis-
tance from Africa increases. Henn et al. were interested
specifically in deleterious variation and focused on the
geographic patterns of this type of variation. Using a set
of samples from seven different human populations, they
found evidence of a serial founder effect in populations
that moved out of Africa. Although purifying selection
was detected at conserved positions in African populations,
some deleterious variants in the non-African populations
acted almost neutrally. This could occur because of the
reduced effective population size at the migratory front.
There, selection would be weaker as genetic drift became a
more powerful force on genetic variation, yielding some
random increases in the frequency of deleterious recessive
alleles. In fact, the authors document that populations
from outside Africa have a higher number of deleterious
alleles per individual than do African populations.
Henn et al. (2016). Proc. Natl. Acad. Sci. USA. 113, E440–
E449.Population Datasets Yield Penetrance Estimates
for Prion Disease
Even in the realm of rare diseases, big data are becoming a
powerful force. Large population datasets have been game
changers in human genetics by increasing our understand-
ing of everything from human history to clinical testing.
Vallabh Minikel et al. realized that coupling these with a
large subject dataset would make the data even more
powerful. The researchers brought together an interna-
tional collection of more than 16,000 subjects with
prion disease and compared genotypes at PRNP in these
individuals to those of general-population samples from
the Exome Aggregation Consortium and 23andMe. As ista, GA 30322, USA
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becoming fairly standard, the researchers use the popula-
tion data to refute the pathogenicity of some PRNP vari-
ants, but they go one step further. Although certain
missense variants were present in the control individuals
at a higher frequency than would be expected if they cause
fully penetrant, autosomal-dominant disease, some were
also more abundant in the affected individuals than in
the general population. Putting the datasets together al-
lowed them to estimate penetrance for these variants and
contrast them with the classic, fully penetrant pathogenic
variants in the same gene. More than one outcome was
also predicted for truncating PRNP variants. These variants
are generally thought of as classic mutations, but in the
case of PRNP, truncating variants were found in both the
general population and the affected individuals. The au-
thors recognized that a clustering of these variants with
C-terminal truncations appeared in affected individuals
and that variants with N-terminal truncations appeared
in healthy control individuals, presumably because the
longer the protein, the more likely it is to have a domi-
nant-negative effect.
Vallabh Minikel et al., (2016). Sci. Transl. Med. 8, 322ra9.404 The American Journal of Human Genetics 98, 403–404, March 3Major Cause of Autosomal-Dominant Oocyte
Meiotic Arrest Is Identified
Human females initiate meiosis prenatally, but the process
is arrested in meiosis I until a hormonal signal triggers the
process to resume, producing a metaphase II oocyte that
can be fertilized. In a few women, the meiosis never re-
sumes after the arrest, and these women are infertile.
Feng et al. identified a family in whom this complete arrest
of oocyte maturation affects five women. The meiotic ar-
rest was detected when two of these women attempted
in vitro fertilization. Exome sequences of affected and un-
affected family members led to the identification of a
missense variant in TUBB8, which encodes a primate-spe-
cific b-tubulin whose function is unknown. Sequencing
this gene in 23 additional affected women identified six
more with a putative pathogenic variant. Of the variants,
five were inherited paternally, and two were de novo in
the affected women. Microinjection of mutant TUBB8
RNA into oocytes recapitulated the meiotic arrest and
affected meiotic-spindle formation.
Feng et al. (2016). N. Engl. J. Med. 374, 223–232.This Month in Our Sister JournalsGene-Set Association Tests Using Summary
Statistics
Traditional marker-based association analysis looks at
each marker individually and has limited power to detect
alleles with a small effect. One approach to identifying
this variation is to use a gene-set approach, in which vari-
ation in a group of genes whose products work together
are considered en masse with the idea that the combined
signal will rise to a detectable level. Using this rationale,Huang et al. propose FLAGS (flexible and adaptive test
for gene sets), a method that uses summary statistics
rather than raw genotype data. Using real datasets for
Crohn disease and bipolar disorder, they tested FLAGS
and compared it to other methods. FLAGS was able to
find the positive-control gene sets for both diseases and
to implicate novel gene sets in the development of these
conditions.
Huang et al. (2016). Genetics. Published online January 15,
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